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Abstract 
 
Prodrug is pharmacologically inactive molecule of an active drug molecule that prior 
to exert its pharmacological effect requires an enzymatic and/or chemical transformation to 
release the active parent drug. Prodrugs can be used to bypass physicochemical, 
pharmaceutical, pharmacokinetic and pharmacodynamic barriers of drug formulation, such 
as poor aqueous solubility, chemical instability, insufficient oral absorption, rapid 
presystemic metabolism, inadequate tissue penetration, toxicity and local irritation. 
In recent years, the design of drugs and prodrugs has increasingly relied on computer 
modeling techniques. This type of modeling is often referred to computer-aided drug 
design which uses computational chemistry to discover, enhance, or study drugs and 
related biologically active molecules. Several enzyme models were evaluated using 
computational chemistry for the purpose to design prodrugs by which their linkers mimic 
the chemistry of enzyme models. Using the enzyme model approach and based on DFT 
calculations three different 6-aminocaproic acid prodrugs were designed, synthesized and 
characterized by FT-IR, 1H-NMR, LC-MS, and their in vitro intra-conversion to their 
parent drugs revealed that the t1/2 value was largely affected by the pH of the medium. For 
6-aminocaproic acid ProD1 the experimental t1/2 values in 1N HCl, buffer pH 2.5 and 
buffer pH 5 were 11 hours, 20.6 hours and 23.4 hours, respectively. 6-aminocaproic acid 
ProD2 was found to be readily intraconverted at 1N HCl, while at pH 2.5 its half-life was 
15 hours and at pH 5 it was 19.5 hours, whereas it was stable at pH 7.4. On the other hand, 
6-aminocaproic acid ProD3 was stable in all studied media.  
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              Chapter One 
 
Introduction 
1.1 Background 
The prodrug (predrug, proagent) term was introduced for the first time by Albert as a 
pharmacologically inactive moiety which is converted to an active form within the body 
[1]. This term has been successfully used to alter the physicochemical, pharmacokinetic 
properties, (absorption, distribution, excretion and metabolism) of drugs and to decrease 
their associated toxicity [2]. The prodrug approach is used to minimize the undesirable 
drug properties while retaining the desirable therapeutic activity. Currently, 5-7 % of all 
approved drugs worldwide can be classified as prodrugs and in the years 2001 and 2002 
approximately 15 % of all new launched drugs were prodrugs [3]. 
 
The prodrug is pharmacologically inactive molecule of an active drug molecule that 
prior to exert its pharmacological effect requires an enzymatic and/or chemical 
transformation to release the active parent drug. Prodrug can be used to bypass 
physicochemical, pharmaceutical, pharmacokinetic and pharmacodynamic barriers of drug 
formulation, such as poor aqueous solubility, chemical instability, insufficient oral 
absorption, rapid presystemic metabolism, inadequate tissue penetration, toxicity and local 
irritation [3, 4]. 
 
Recently Drug design become increasingly relying on computer modeling techniques. 
This type of modeling is often referred to as computer-aided drug design by which 
computational chemistry methods are used to discover, enhance, or study drugs and related 
biologically active molecules [5]. Recently, numerous novel prodrugs have been designed 
by Karaman’s group for the treatment of Parkinson's disease (dopamine), malaria 
(atovaquone) , viral infections(amoxicillin) , hypertension (atenolol) and etc.. Using DFT 
(density functional theory) calculations methods, Karaman’s group studied a significant 
number of intermolecular processes (enzyme models). Based on the calculation results they 
designed linkers to be linked to amino- and hydroxyl- containing drugs such that the 
proposed prodrugs will have a moderate HLB value. The combination of both hydrophilic 
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and lipophilic groups is expected to give better bioavailability due to moderate 
hydrophilic- lipophilic balance value [6-8]. 
Applications of prodrug approach 
A. Improving solubility and bioavailability 
Poor solubility of drug will be a challenge when dissolution of the drug  in a dosage form 
is the rate limiting step. Many techniques are used to overcome solubility problems as salt 
formation and solubility enhancer excipients. Prodrugs can also be used as an alternative 
technique to increase aqueous solubility of parent drug by attaching polar groups such as 
phosphate, amino acids and sugar moieties [9-11]. 
If the prodrug contains a phosphate group, the parent drug will be readily released  by 
endogenous phosphatase as alkaline phosphatase, while if it contains amino acid esters or 
amides the prodrug will be cleaved by esterase or amidase available in plasma or tissues, 
and if it contains sugar moieties such as glucose, -glucosidase will be utilized to convert 
the prodrug to its corresponding parent drug [12]. 
 
B. Increasing permeability and absorption 
For a drug to be absorbed it should pass through many membranes. This requires a 
lipophilic group to be in the drug structure so if the drug contains polar groups it will have 
a limited permeability and then a low absorption profile. The prodrug strategy can be used 
to enhance permeability by masking the polar group as hydroxyl, thiol, carboxyl, 
phosphate or amino acid with more lipophilic alkyl or aryl esters and these prodrugs can be 
readily converted to the parent drugs via hydrolysis catalyzed by esterase enzyme [13]. 
 
C. Changing distribution profile 
This approach can be accomplished using a prodrug to deliver a parent drug to a specific 
target utilizing site- selective endogenous enzymes to convert the prodrug to its active 
parent drug. In addition, this approach may also be used to decrease drug toxicity [12]. 
 
D. Improving taste 
If a drug has unpleasant taste, it will decrease the patient compliance. Prodrugs can be used 
to improve the taste of the parent drugs either by decreasing their solubility in saliva or by 
masking the functional group that is responsible for the binding to the taste receptors 
located on the tongue and thus to reduce the unpleasant taste [14]. 
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Successfully designed prodrug should be activated to its parent drug; activation process 
involves metabolism by enzymes distributed throughout the body, hydrolytic enzymes as 
esterases and amidases and non-hydrolytic enzymes such as cytochrome P450 are the most 
important enzymes involved in the bioactivation process of prodrugs. 
Enzymes accelerate the rate of chemical reactions that the substrate (drug) might undergo 
in physiological environment. The reaction rate in the majority of enzymatic reactions is 
1010 to 1018 fold than non-enzymatic reaction [15]. 
When the prodrug is designed to be activated by natural enzymes such as esterases and 
amidases, the prodrug might be tackled by a premature hydrolysis during the absorption 
phase in enterocytes of gastrointestinal tract. This might produce more polar and less 
permeable prodrug which results in a decreased bioavailability (50%).  While if the 
prodrug is activated by cytochrom P450 enzymes which are responsible for 75% of the 
enzymatic metabolism of prodrugs, a genetic polymorphisms might persist and then lead to 
variability in prodrug activation and thus affect the efficacy and safety of designed 
prodrugs [15].  Thus, it might be difficult to predict the bioconversion rate of the 
enzymatic hydrolysis of the prodrug and hence a difficulty in predicting their 
pharmacological or toxicological effects.  
In the past few decades, computational chemistry has been utilized in calculating 
physicochemical and molecular properties of compounds. Using molecular orbital (MO) 
and molecular mechanics (MM) methods prediction of chemical reactions can be done.  
This tool can be used to design prodrugs that can be chemically interconvert to their parent 
drugs without any involvement of enzyme catalysis. The release of the active drug will be 
solely dependent on the rate limiting step of the intramolecular process (prodrug chemical 
features) [16].  
 
Prodrugs classification: 
The conventional method used to classify prodrugs is based on derivatization and the type 
of carriers attached to the drug. This method classified prodrugs into two sub-major 
classes: 
(1) Carrier-linked prodrugs, in which the promoiety covalently linked to the active drug but 
it can be easily cleaved by enzymes (such as an ester or labile amide) or non-
enzymatically to provide the parent drug. Ideally, the group removed is 
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pharmacologically inactive, nontoxic, and non-immunogenic, while the promoiety 
must be labile for in vivo efficient activation [17, 18]. 
Carrier-linked prodrugs can be further subdivided into: (a) bipartite which is composed 
of one carrier (promoiety) attached directly to the drug, (b) tripartite which utilizing a 
spacer or connect a group between the drug and a promoiety. In some cases bipartite 
prodrug may be unstable due to inherent nature of the drug-promoiety bond.  This can 
be overcome by designing a tripartite prodrug and (c) mutual prodrugs, which are 
consisting of two drugs linked together. 
(2) Bioprecursors which are chemical entities that are metabolized into new compounds 
that may be active or further are metabolized to active metabolites (such as amine to 
aldehyde to carboxylic acid). In this prodrug type there is no carrier but the compound 
should be readily metabolized to induce the necessary functional groups [2, 19, 20]. 
 
1.2. 6-Aminocaproic acid 
 
6-Aminohexanoic acid (Figure 1) is a synthetic lysine analog that suppresses fibrinolytic 
activity by fitting into plasminogen´s lysine-binding site and preventing the binding of 
plasminogen to fibrin [21]. 
It is an anti fibrinolytic drug used to control bleeding that occurs when blood clots are 
broken down too quickly (such as during or after heart surgery; in people who have certain 
bleeding disorders; prostate, lung, stomach, or cervical cancer; and in pregnant women 
when the placenta separates from the uterus before the baby is ready to be born), it is also 
used to control bleeding in the urinary tract that may occur after prostate or kidney surgery 
[22]. 
Studies on this drug have showed a clinical benefit in decreasing mortality and morbidity 
in many traumatic cases and different types of surgery like coronary artery bypass grafting 
in which the administration of 6-aminocaproic acid resulted in a significant decrease in 
blood loss and blood transfusion requirements were significantly less [23]. 
Also the administration of this drug can reduce blood loss and consequently transfusion 
and transfusion-related risk in patient who undergo hip replacement [24]. 
As well as, it can reduce the incidence of secondary hemorrhage following traumatic 
hyphema [25]. It plays an important role in dental extraction in patients with hemophilia 
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[26], and in control hemorrhage in patients with amegakaryocytic thrombocytic 
thrombocytopenia [27]. 
 
There are other antifibrinolytic drugs, such as aprotinin, and tranexamic acid, used 
intraoperatively, postoperatively, and during extracorporeal membrane oxygenation 
(ECMO) to reduce bleeding and minimize the need for exogenous blood products. 
However, because of risk of renal failure, cardiac failure, stroke, or encephalopathy that 
are associated with the use of aprotinin, the latter was removed from the market., Hence, 6-
aminocpaproic acid and tranexamic acid are potentially safer alternatives [22]. In the UK, 
tranexamic acid, a tissue plasminogen and plasmin inhibitor, is most commonly used, with 
evidence for benefit in cardiac, orthopaedic, urological, gynaecological, and obstetric 
surgery. In the USA, aminocaproic acid, which also inhibits plasmin, is commonly used 
[22]. 
 
O
HO
NH2
 
 
1.3. Research problem 
The bioavailability of 6-aminocaproic acid is only 24%. This low value is attributed 
to the amino acid nature of the drug. At physiological pH, 6-aminocaproic acid will exist 
mainly in the ionized form; this ionization will decrease the ability of 6-aminocaproic acid 
to be transferred to the systemic blood circulation. This limited permeation results in poor 
bioavailability of the anti-bleeding drug [28]. 
Thus, using the prodrug approach to increase 6-aminocaproic acid bioavailability can be 
utilized. This can be achieved by making a covalent linkage between 6-aminocaproic acid 
and a non-toxic promoiety that increases the lipophilicity of 6-aminocaproic acid.  
The proposed prodrug was designed such that the prodrug will be chemically 
intraconverted to 6-aminocaproic acid and a non-toxic moiety in a rate which is only 
dependent on the structural features of the inactive linker. 
 
 
 
Figure 1. Chemical structure of 6-aminocaproic acid. 
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1.4. Thesis objectives 
General Objective: 
The main goal of this research was to synthesize and to study the kinetics for the following 
novel prodrugs: 6-aminocaproic acid maleate, 6-aminocaproic acid dimethyl maleate, 6-
aminocaproic acid succinate. 
 
Specific objectives: 
1. To synthesize 6-aminocaproic acid prodrugs with the following characteristics: 
 To be readily dissolved in physiological media. 
 To have an increased bioavailability profile. 
 To have moderate hydrophilic lipophilic balance (HLB) value. 
 To be converted to 6-aminocaproic acid in a programmable manner. 
 To give a safe non-toxic linker moiety after the chemical conversion process. 
2. To perform in vitro kinetic studies of 6-aminocaproic acid prodrugs at different pHs 
mimicking the physiological media. 
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Chapter Two 
2. Literature Review 
2.1.  Introduction 
Nowadays, quantum mechanics (QM) such as ab initio, semi-empirical and density 
functional theory (DFT) and molecular mechanics (MM) are recommended to provide 
structure energy calculations for prediction of drugs and prodrugs alike [29-33]. 
The ab initio molecular orbital methods are based on rigorous use of Schrodinger equation 
with number of approximations. ab initio methods can be applied only on small system 
containing not more than thirty atoms. Semi-empirical method is applied on molecules 
with more than 50 atoms and gives information for practical application [34,35]. DFT 
method is a semi-empirical method used for medium sized systems and it is not restricted 
to the second row of the periodic table [36]. 
The mechanisms of some intramolecular processes that were advocated to understand 
enzyme catalysis (enzyme models) were investigated by Karaman’s group to design novel 
prodrug linkers [37, 38-56]. Among the studied intramolecular processes:  
o Acid-catalyzed lactonization of hydroxy-acids as researched by Cohen [31-57, 58] and 
Menger [59-65]. 
o SN2-based ring closing reactions as studied by Brown, Bruice, and Mandolini [32, 33, 
66]. 
o Proton transfer between two oxygens in Kirby’s acetals [67-71], and proton transfer 
between nitrogen and oxygen in Kirby’s enzyme models [67-71] and proton transfer 
from oxygen to carbon in some of Kirby’s enol ethers [67-71]. 
 
The computational calculations using DFT and ab initio methods carried by Karaman’s 
group revealed the followings: (i) rates acceleration in intramolecular processes are a result 
of both entropy and enthalpy effects. In intramolecular ring-closing reactions where 
enthalpic effects were predominant, steric effects were the determining factor for the 
acceleration, whereas proximity orientation was the determining factor in proton-transfer 
reactions. (ii) The distance between the two reacting centers is the main factor in 
determining whether the reaction type is intermolecular or intramolecular.  When the 
distance exceeded 3 Å, an intermolecular engagement was preferred because of the 
engagement with a water molecule (solvent). When the distance between the electrophile 
and nucleophile was < 3 Å, an intramolecular reaction was dominant [38-55, 72]. 
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Based on previous studies on enzyme models a design of a prodrug with modified 
pharmacokinetics properties that can releases the parent drug in a slow or fast manner 
could be accomplished [73]. 
 
2.2.  Design of 6-aminocaproic acid prodrug using Kirby`s enzyme model (Proton 
transfer in N-alkylmaleamic acids) 
Acid-catalyzed hydrolysis of N-alkylmaleamic acids 1-9 (Figure 2) was kinetically studied 
by Kirby’s group; they concluded that the amide bond cleavage occurs due to 
intramolecular nucleophilic catalysis by the adjacent carboxylic acid group and the rate-
limiting step is the tetrahedral intermediate breakdown [74]. 
 
 
Figure 2. Acid-catalyzed hydrolysis of N-alkylmaleamic acids. 
 
DFT calculations on the acid-catalyzed hydrolysis of Kirby`s N-alkylmaleamic acids that 
were done by Karaman’s group showed that the rate limiting step in aqueous medium is 
the collapse of the tetrahedral intermediate  whereas in the gas phase the rate limiting step 
is the formation of the tetrahedral intermediate. Furthermore, Karaman’s calculations 
revealed a correlation between the acid-catalyzed hydrolysis efficiency and the following 
parameters: 
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1. The difference in the strain energies of the ground states along the reaction pathway, 
reactants, intermediates and products..  
2. The distance between the hydroxyl oxygen of the carboxylic group and the amide 
carbonyl carbon. 
3. The attack angle of the carboxylate oxygen and the amide carbonyl carbon.  
 
The calculations also demonstrated that the acid catalyzed reaction involves three 
steps: (1) proton transfer from the carboxylic group to the adjacent amide carbonyl oxygen, 
(2) nucleophilic attack of the carboxylate anion onto the protonated carbonyl carbon; and 
(3) dissociation of the tetrahedral intermediate to provide products (Figure 3)  
 
 
 
Figure 3. Proposed mechanism for the acid-catalyzed hydrolysis of N-alkylmaleamic  
acids. 
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Based on the calculation results of Kirby`s model (proton transfer in N-alkylmaleamic 
acids) we propose three 6-aminocaproic acid prodrugs, 6-aminocaproic acid ProD1- 3 
(Figure 4). 
As shown in Figure 4, 6-aminocaproic acid ProD1-3 have a carboxylic group (hydrophilic 
moiety) and a lipophilic moiety (the rest of the prodrug), where the combination of both 
moieties secures a relatively moderate HLB. 
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Figure 4. Acid-catalyzed hydrolysis of 6-aminocaproic acid ProD1- 3. 
 
In most of the  physiologic environments (pH 1- 8.0) 6-aminocaproic acid will exist 
primary in the ionized forms (eq.1) while its prodrugs, 6-aminocaproic acid ProD1- 3, will 
equilibrate between the ionic and the free acid forms (eq. 2) especially in a physiological 
environment of  pH 5.5-6.8 (intestine). Thus, it is expected that 6-aminocaproic acid 
ProD1- 3 may have a better bioavailability than the parent drug due to neutralizing the 
ionized amine group which results in absorption improvement. In addition, these prodrugs 
may be used in different dosage forms (i.e. enteric coated tablets, topical use and etc.) 
because of their potential solubility in organic and aqueous media due to the ability of the 
carboxylic group to be converted to the corresponding carboxylate anion in a physiological 
pH of around 6.0. 
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It should be emphasized that at pH 5.5-6.5 (SC, skin, mouth cavity and intestine 
physiologic environments), the carboxylic group of the prodrugs will equilibrate with the 
corresponding carboxylate form (eq. 2). Subsequently, the free acid form will undergo 
proton transfer reaction (rate limiting step) to yield the antifibrinolytic drug, 6-
aminocaproic acid, and the inactive linker as a by-product (Figure 4).  
It is worth noting that our proposal is to exploit 6-aminocaproic acid prodrugs ProD1- 3 
for oral use via enteric coated tablets. At this physiologic environment, these prodrugs will 
exist in the acidic and ionic forms where the equilibrium constant for the exchange 
between the two forms is dependent on the pKa of the given prodrug (eq. 2). The 
experimental determined pKa1 for 6-aminocaproic acid ProD1- 3 linkers is in the range of 
4-6. Therefore, it is expected that the pKas of the corresponding prodrugs will have similar 
pKa range as for the carboxylic linkers. Since the pH for the small intestine lies in the 
range of 5.5-6.8, the calculated unionized (acidic) /ionized ratio will be in the range of 10-
50%. Although the percentage of the acidic form is not significantly high, we expect that 
these prodrugs to undergo an efficient proton transfer (rate limiting step) to yield the 
antifibrinolytic drug, 6-aminocaproic acid. In the blood circulation at pH 7.4, the calculated 
acidic form is around 1% and it is expected that the efficiency for delivering the parent 
drug will be relatively low. Improving the efficiency could be achieved by using 
carboxylic linkers having pKa close to that of the blood circulation (pH 7.4 
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Chapter Three 
 
3.1 Materials and methods 
This chapter contains three parts: the first part is devoted to the description of the 
chemicals and reagents used throughout the study, the second part describes the 
instruments used, and the last part deals with specific preparation and analysis of prodrugs 
6-aminocaproic acid with maleic anhydride, 6-aminocaproic acid with dimethyl maleic 
anhydride and 6-aminocaproic acid with succinic anhydride. 
Part one  
3.1.1 Chemicals and Reagents 
Pure standards of 6-aminocaproic acid, maleic anhydride, 2,3- dimethyl maleic anhydride, 
succinic anhydride, sodium hydroxide (NaOH), tetrahydrofuran (THF), ethyl acetate, 
distilled water (D.W), methanol, chloroform, acetone, and water for analysis were for 
HPLC grade and were  purchased from Sigma Aldrich Company. 
 
Part two 
 3.2 Instrumentation 
3.2.1 High Pressure Liquid Chromatography  
High Pressure Liquid Chromatography (HPLC-PDA) system consists of an alliance 2695 
HPLC from (Waters: Israel), and a waters Micromass® Masslynx ™ detector with Photo 
diode array (PDA) (Waters 2996: Israel). Data acquisition and control were carried out 
using Empower ™ software (Waters: Israel). Analytes were separated on a 4.6 mm 
x150mm C18 XBridge ® column (5 µm particle size) used in conjunction with a 
4.6mmx20 µm XBridge ™ C18 guard column. Microfilter was used with 0.45 µm 
(Acrodisc® GHP, Waters).  
     
3.2.2  UV-Spectrophotometer  
The concentrations of the samples were determined spectrophotometrically (UV-
spectrophotometer, Model: UV-1601, Shimadzu, Japan) by monitoring the absorbance at 
the λmax for the drug and prodrug. 
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3.2.3 pH meter  
pH values were recorded on pH meter model HM-30G: TOA electronics ™ was used in 
this study to measure the pH value for each sample. 
 
3.2.4 Fourier Transforms Infrared Spectroscopy (FTIR): 
All infrared spectra were obtained from a KBr matrix (4000–400 cm-1) using a 
PerkinElmer Precisely, Spectrum 100, FT-IR spectrometer.  
 
3.2.5 1HNMR 
Data were collected using Varian Unity Inova 500 MHz spectrometer equipped with a 5-
mm switchable and data were processed using the VNMR software. For 1H-NMR, 
chemical shifts are reported in parts per million (ppm, δ) downfield from tetramethylsilane 
(TMS). Spin multiplicities are described as s (singlet), brs (broad singlet), t (triplet), q 
(quartet), and m (multiplet). 
 
3.2.6 Rotary Evaporator 
Speed Control: 20-270 rpm, Digital bath for water or oil 20-180oC, ±1oC, Bath can also be 
used separately, Distillation glass set type G1 (Standard diagonal condenser). 
 
3.2.7 LC-MS 
HPLC–MS/MS measurements were performed employing a Shimadzu prominence high 
performance liquid chromatography system (Shimadzu corp. Japan). 
 
 Part three (Scheme1)   
3.3 Synthesis methods 
3.3.1 6-aminocaproic acid ProD1 
In a 250 ml RBF, 20 mmol of 6-aminocaproic acid white  powder  was dissolved in THF 
(100 ml), 0.5 gm of sodium hydroxide (NaOH) were dissolved in 2ml D.W and the 
resulting solution was added and the reaction mixture was stirred, after 30 minutes 20 
mmol of maleic anhydride was slowly added to the reaction mixture and stirred at room 
temperature for 24 hours, then the solvent was evaporated till dryness. The resulted white 
powder was washed using ethyl acetate  and dried. the reaction was monitored using TLC 
with eluent (chloroform: methanol 3:1). Then final product was characterized using 1H-
NMR, LC-MS and IR. 
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6-aminocaproic acid ProD1: White solid with M.P. 85 Co; 1H-NMR δ (ppm) CD3OD- 1.42 
(m, 2H, CH2-CH2- CH2),  1.56 (m, 2H, CH2-CH2-CH2-CH2), 1.60 (m, 2H, CH2-CH2-CH2-
CH2), 2.20(t, 2H, COO-CH2-CH2), 2.96 (t, 2H, CH2-CH2-NH), 6.10 (d, 1H, J = 10 Hz, 
HC=CH), 6.27 (d, 1H, J = 12 Hz, HC=CH). IR (KBr/νmax cm–1) 1782 (C=O), 1707 (C=O), 
1570 (C=C), 1404, 1283, 1189, 1104, 1062. m/z 252 (M+Na)+. Yield: 96% (4.8 g). 
 
3.3.2  6-aminocaproic acid ProD2 
In a 250 ml RBF, 20 mmol of 6-aminocaproic acid was dissolved in THF (100 ml), 0.5 gm 
of sodium hydroxide (NaOH) were dissolved in 2ml D.W and the resulting solution was 
added and the reaction mixture was stirred, after 30 minutes 20 mmol of dimethyl maleic 
anhydride was slowly added to the reaction mixture and stirred at room temperature for 24 
hours, then the solvent was evaporated till dryness. The resulted white powder was washed 
using ethyl acetate and dried. the reaction was monitored using TLC with eluent 
(chloroform: methanol 3:1) . Then final product was characterized using 1H-NMR, LC-MS 
and IR. 
 
6-aminocaproic  acid ProD2: White solid with M.P. 158 Co; 1H-NMR δ (ppm) CD3OD- 
1.42 (m, 2H,CH2- CH2- CH2-CH2), 1.56 (m, 2H, CH2-CH2-CH2-CH2), 1.62 (m, 2H, CH2-
CH2-CH2-CH2),1.93 (s,6H, CH3-C=C-CH3), 2.20 (t, 2H, COO-CH2 -CH2), 2.96(t, 2H, 
CH2-CH2-NH), IR (KBr/νmax cm–1) 1850 (C=O), 1782(C=O), 1581(C=C), 1389, 1282, 
1204, 1105,1057. m/z 279 (M+Na)+. Yield: 91.4% (2.35 g). 
 
3.3.3  "6-aminocaproic acid ProD3"  
In a 250 ml RBF, 20 mmol of 6-aminocaproic acid was dissolved in THF (100 ml), 0.5 gm 
of sodium hydroxide (NaOH) were dissolved in 2ml D.W and the resulting solution was 
added and the reaction mixture was stirred, after 30 minutes 20 mmol of succinic 
anhydride was slowly added to the reaction mixture and stirred at room temperature for 24 
hours, then the solvent was evaporated till dryness. The resulted white powder was washed 
using ethyl acetate and dried.  the reaction was monitored using TLC with eluent 
(chloroform: methanol 3:1) . Then final product was characterized using 1H-NMR, LC-MS 
and IR. 
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6-aminocaproic  acid ProD3: White solid with M.P. 100 Co;  1H-NMR δ (ppm) CD3OD- 
1.35 (m, 2H CH2-CH2-CH2), 1.50 (m, 2H, CH2-CH2-CH2-CH2), 1.6 5(m, 2H, CH2-CH2-
CH2-CH2), 2.24(t, 2H, COO-CH2 -CH2), 2.45 (t, J = 6 Hz, 2H,CH2-CH2), 2.51 (t, 2H, J = 
6.4 Hz, CH2-CH2), 2.96 (t, 2H, CH2-NH). IR(KBr/νmax cm–1) 1632(C=O), 1554(C=O), 
1474, 1414, 1366, 1239, 1200, 1166, 1028. m/z 254 (M+Na)+. Yield: 94% (4.36 g). 
 
 
 
 
 
c)      )  
 
 
Scheme 1: Synthesis of (a) 6-aminocaproic acid ProD1, (b) 6-aminocaproic acid ProD2, 
(c) 6-aminocaproic acid ProD3. 
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3.4 Kinetic Methods 
3.4.1 Buffer Preparation 
6.8 g potassium dihydrogen phosphate were dissolve in 900 ml water for HPLC, the pH of 
buffer pH 2.5 was adjusted by diluted  o- phosphoric acid and water was added to a final 
volume of 1000 ml (0.05M). The same procedure was done for the preparation of buffers 
pH 5 and 7.4. However, the required pH was adjusted using 1 N NaOH. 
Inter conversion of 500 ppm 6-aminocaproic acid ProD1-3 solutions, in 1N HCl, buffer 
pH 2.5, buffer pH 5 or buffer pH 7.4, to its parent drug, 6-aminocaproic acid, was followed 
by HPLC at a wavelength of 210 nm. Conversion reactions were run mostly at 37.0 ˚C.  
 
3.4.2 Calibration curve 
A 100 ml stock solution of 6-aminocaproic  acid ProD1-3 with a final concentration of 50 
ppm were prepared by dissolving 500 mg from each prodrug in 100 ml methanol. The 
following diluted solutions were prepared from the stock solution: 100, 200, 300 and 400 
ppm. Each solution was then injected to the HPLC apparatus using 6 mm x 250 mm, 5 µm 
C18 XBridge ® column, mobile phase contains (pH 2.5 using diluted phosphoric acid), a 
flow rate of 1 ml min-1 and UV detection at a wavelength of 210 nm. 
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R2 of the 
plot was recorded. 
 
3.4.3 Preparation of standard and sample solution 
6-aminocaproic acid prodrugs 
A 500 ppm of standard 6-aminocaproic acid was prepared by dissolving 50 mg of 6-
aminocaproic acid in 100 ml of 1N HCl, buffer pH 2.5, buffer pH 5 or buffer pH 7.4, then 
each sample was injected into HPLC to detect the retention time of 6-aminocaproic acid. 
A 500 ppm of standard linker (maleic anhydride, 2,3-dimethyl maleic anhydride, succinic 
anhydride) was prepared by dissolving 500 mg of each linker in 100 ml of 1N HCl, buffer 
pH 2.5, buffer pH 5 or buffer pH 7.4, then each sample was injected into HPLC to detect 
the retention time of linker. 
A 500 ppm of each 6-aminocaproic  acid ProD1-3 was prepared by dissolving 50 mg of 
the 6-aminocaproic acid ProD1-3 in 100 ml of 1N HCl, buffer pH 2.5, buffer pH 5 or 
buffer pH 7.4 then each sample was injected into HPLC to detect the retention time. 
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The progression of reaction was followed by monitoring the disappearance of the prodrug 
and the appearance of the linkers, maleic anhydride, 2,3-dimethyl maleic anhydride and 
succinic anhydride with time. 
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Chapter Four 
 
4. Results and Discussion 
        6-aminocaproic acid prodrugs were synthesized, purified and characterized using 
different spectroscopic and chromatographic techniques.  
4.1. Characterization 
6-aminocaproic acid and 6-aminocaproic acid ProD1- 3 were characterized by FT-IR, LC-
MS and 1H-NMR spectroscopy. 
6-aminocaproicacid (C6H13NO2). The IR spectrum (Figure 5a) shows an absorbance at 
1655 cm-1 corresponds to C=O, 1453 cm-1, 1291 cm-1, 1212 cm-1, 1104 cm-1, 1044 cm-1. 
The 1H-NMR (Figure 6 b) peaks correspond to 1.42 ppm (m, 2H, CH2-CH2-CH2), 1.55 
ppm (m, 2H, CH2-CH2-CH2-CH2), 1.56 ppm (m, 2H, CH2-CH2-CH2-CH2), 2.23 ppm (t, 
2H, COO-CH2-CH2-), 2.96 ppm (t, 2H,CH2CH2-NH2). 
 
Figure 5a. FT-IR spectrum of 6-aminocaproic acid. 
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Figure 5b. 1H-NMR spectrum of 6-aminocaproic acid in CD3OD. 
 
6-aminocaproicacid ProD1 (C10H15NO5).The zoomed IR spectrum (Figure 6a)  shows an 
additional signals with absorbance 1782 cm-1, 1707 cm-1 corresponds to C=O of the 
maleate moiety. A high resolution LC-MS (Figure 6 b) shows a protonated peak adduct of 
[M+Na]+ was appeared at m/z of 252.0839. The 1H-NMR (Figure 6 c) the alkene cis 
protons show doublet peaks at 6.10 ppm and 6.27 ppm with coupling constant of 10 Hz, 
indicates the cis arrangement of these protons. 
Figure 6a. FT-IR spectrum of 6-aminocaproic acid ProD1. 
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Figure 6b. LC-MS spectrum of 6-aminocaproic acid ProD1. 
 
 
Figure 6c.1H-NMR spectrum of 6-Aminocaproic acid ProD1in CD3OD. 
 
6-aminocaproic acid ProD2 (C12H19NO5). The zoomed IR spectrum (Figure 7a) shows an 
absorbance of the additional carbonyl group (C=O) for the dimethyl maleate moiety at 
1850 cm-1 and 1782 cm-1. A high resolution LC-MS (Figure 7 b) shows a protonated peak 
for adduct [M+Na]+ at m/z 279.1605. The 1H-NMR (Figure 7 c) an additional singlet peak 
occurs at 1.93 ppm represenst the two methyl groups on C=C of the dimethyl maleate 
moiety. 
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Figure 7a. FT-IR spectrum of 6-aminocaproic acid ProD2. 
 
Figure 7b. LC-MS spectrum of 6-aminocaproic acid ProD2. 
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Figure 7c. 1H-NMR spectrum of 6-aminocaprroic acid ProD2 in CD3OD. 
 
6-amincaproic acid ProD3 (C10H17NO5). The IR spectrum (Figure 8a) shows an 
absorbance at 1632 cm-1 corresponds to the additional carbonyl group (C=O) for the 
succinate moiety. A high resolution LC-MS shows a protonated peak at adduct of 
[M+Na]+m/z 254.0999 (Figure 8b). The 1H-NMR (Figure 8c) shows an additional triplet 
signal for the succinate moiety protons which show a singlet peak at 2.45 ppm with 
coupling constant of 6 Hz. 
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Figure 8a. FT-IR spectrum of 6-aminocaproic acid ProD3. 
 
Figure 8b. LC-MS spectrum of 6-aminocaproic acid ProD3. 
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Figure 8c. 1H-NMR spectrum of 6-aminocaproic acid ProD3 in CD3OD. 
 
The IR, 1H-NMR and LC-MS spectra results mentioned before, confirmed that the desired 
prodrugs are obtained from each reaction. 
 
4.2 Calibration curve for 6-aminocaproic acid ProD1- 2 
In order to follow the prodrugs kinetics, calibration curves were obtained by plotting the 
HPLC peak area versus concentration for each prodrug as displayed in Figures 9a and 9b.  
As shown in the figures, excellent linearity with correlation coefficient (R2) of 0.992 6-
aminocaproic acid ProD1 (Figure 9a) and 0.983 for 6-aminocaproic acid ProD2 (Figure 
9b) were obtained. 
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Figure 9a. Calibration curves for 6-aminocaproic acid ProD1. 
 
Figure 9b. Calibration curves for 6-aminocaproic acid ProD2. 
4.3 Hydrolysis studies 
4.3.1 6-aminocaproic acid ProD1-3 
The kinetics of the acid-catalyzed hydrolysis studies were carried out in aqueous buffer in 
the same manner as that done by Kirby on Kirby’s enzyme model 1-9 [73]. This is in order 
to explore whether the prodrug hydrolyzes in aqueous medium and to what extent, 
suggesting the fate of the prodrug in the system. Acid-catalyzed hydrolysis kinetics of the 
synthesized 6-aminocaproic acid ProD1-3 were studied in four different aqueous media, 
1N HCl, buffer pH 2.5, buffer pH 5 and buffer pH 7.4.  
Under the experimental conditions, the target compounds hydrolyzed to release the parent 
drug as evident by HPLC analysis. At constant pH and temperature, the reaction displayed 
strict first order kinetics as the kobs was fairly constant and a straight plot was obtained on 
plotting log concentration of residual prodrug vs. time. The rate constant (kobs) and the 
corresponding half-lives (t1/2) for 6-aminocaproic acid prodrugs ProD1-3 in the different 
media were calculated from the linear regression equation correlating the log 
concentrationof the residual prodrug vs. time. The 1N HCl and pH 2.5 were selected to 
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examine the intra-conversion of the 6-aminocaproic acid prodrugs in pH as of stomach, 
because the mean fasting stomach pH of adult is approximately 1-2. In addition, buffer pH 
5 mimics the beginning small intestine pathway. pH 7.4 was selected to examine the intra-
conversion of the tested prodrug in blood circulation system. Acid-catalyzed hydrolysis of 
6-aminocaproic acid ProD1 was found to be higher at 1N HCl than at pH 2.5 and 5 
(Figures 10, 11 and 12). At 1N HCl, the half-life of the prodrug was 11 hours. On the other 
hand, at pH 7.4, the prodrug was entirely stable and no release of the parent drug was 
observed. Since the pKa of 6-aminocaproic acid ProD1 is in the range 3-4, it is expected 
that at pH 5 the anionic form of the prodrug will be dominant and the percentage of the 
free acid form that undergoes the acid-catalyzed hydrolysis will be relatively low. At 1N 
HCl and pH 2.5, most of the prodrug will exist as the free acid form and at pH 7.4 most of 
the prodrug will be in the anionic form. Thus the discrepancy in rates at the different pH 
buffers, the kinetic data are listed in Table 1.   
Acid catalyzed hydrolysis of 6-aminocaproic acid ProD2 was found to be readily 
intraconverted at 1N HCl, while at pH 2.5 the half-life was 15 hours (Figures13) and at pH 
5 it was 19.5 hours (Figures14), while it was stable at pH 7.4; according to structural 
feature of 2,3-dimethyl maleic moiety, it contains two methyl groups on the C-C double 
bond (strained system) which results in a decrease of the distance between the two reactive 
centers (hydroxyl oxygen of the carboxylic group and the amide carbonyl carbon). Hence, 
the hydrolysis in 1N HCl and pH 2.5 of 6-aminocaproic acid ProD2 is faster than that of 6-
aminocaproic acid ProD1 (Figures 15 and 16) 
Table 2 summarized the kinetic data for 6-aminocaproic acid ProD2. 
In the case of 6-aminocaproic acid ProD3 the interatomic distance between the nucleophile 
(OH) and electrophile (C=O) is too high to make the nucleophile attack accessible. Hence, 
no reaction was observed with this prodrug in all different tested buffers (Table 3). 
 
Table 1: The observed k value and1/2 for the intraconversion of 6-aminocaproic acid 
ProD1 in 1N HCl and at pH 2.5, pH 5 and pH 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl 1.39 x 10-4 11 
Buffer pH 2.5 1.70 x 10-4 20.6 
Buffer pH 5 9.6x 10-5 23.4 
Buffer pH 7.4 No reaction No reaction 
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Table 2: The observed k value and t1/2 for the intraconversion of 6-aminocaproic acid 
ProD2 in 1N HCl and at pH 2.5, pH 5 and pH 7.4. 
 
Medium kobs (h-1) t½ (h) 
1N HCl Readily released Readily released 
Buffer pH 2.5 1.01×10-4 15 
Buffer pH 5 5.8×10-5 19.5 
Buffer pH 7.4 No reaction No reaction 
 
Table 3: The observed k value and t1/2 for the intraconversion of 6-aminocaproic acid 
ProD3 in 1N HCl and at pH 2.5, pH 5 and pH 7.4. 
Medium kobs (h-1) t½ (h) 
1N HCl No reaction No reaction 
Buffer pH 2.5 No reaction No reaction 
Buffer pH 5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
 
Figure 10. Chromatograms showing the intra-conversion of 6-aminocaproic acid ProD1 in  
1N HCl (a) at zero time, (b) at the end of reaction. 
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Figure 11. Chromatograms showing the intra-conversion of 6-aminocaproic acid ProD1 at 
pH 2.5 (a) at zero time, (b) at the end of reaction. 
 
 
Figure 12. Chromatograms showing the intra-conversion of 6-aminocaproic acid ProD1 at 
pH 5 (a) at zero time, (b) at the end of reaction. 
 
 
Figure 13. Chromatograms showing the intra-conversion of 6-aminocaproic acid ProD2 at 
pH 2.5 (a) at zero time, (b) at the end of reaction. 
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Figure14. Chromatograms showing the intra-conversion of 6-aminocaproic acid ProD2 at 
pH 5 (a) at zero time, (b) at the end of reaction 
 
 
Figure15. First order hydrolysis plot for the intraconversion of 6-aminocaproic acid 
ProD1 in (a) 1N HCl, (b) buffer pH 2.5 and (c) buffer pH 5. 
 
 
Figure 16. First order hydrolysis plot for the intraconversion of 6-aminocaproic acid 
ProD2 in (a)  buffer pH 2.5 and (b) buffer pH 5. 
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Chapter Five 
 
5. Conclusions and Future directions 
5.1. Conclusions: 
Based on Kirby`s enzyme model (Proton transfer in N-alkylmaleamic acids) three 
different 6-aminocaproic acid prodrugs were synthesized and their acid-catalyzed 
hydrolysis demonstrated that the rate-limiting step was the collapse of the tetrahedral 
intermediate. The experimental t1/2 value for 6-aminocaproic acid ProD1 in 1N HCl, buffer 
pH 2.5 and buffer pH 5 were 11 hours, 20.6 hours and 23.4 hours, respectively. On the 
other hand, no hydrolysis was observed at pH 7.4. The lack of the hydrolysis at pH 7.4 
might be due to the fact that at this pH 6-aminocaproic acid ProD1 exists mainly in the 
ionized form (pKa about 4) taking into consideration that the free acid form is a mandatory 
requirement for the acid-catalyzed hydrolysis to proceed.  
6-Aminocaproic acid ProD2 was readily converted in 1 N HCl and the experimental t1/2 
value measured in buffer pH 2.5 and pH 5 were 15 hours and 19.5 hours, respectively. The 
prodrug was entirely stable at pH 7.4. 
6-Aminocaproic acid ProD3 was stable in 1 N HCl, pH 2.5, pH 5 and pH 7.4 and no 
reaction was observed. This may be due to the long interatomic distance between the 
nucleophile (OH) and electrophile (C=O) which renders any nucleophile attack. Hence 
additional 6-aminocaproic acid prodrugs with reasonable intra-conversion rate at pH 6.5 
and pH 7.4 can be synthesized  
 
5.2. Future directions: 
The study results suggest synthesis of additional 6-aminocaproic acid prodrugs that may be 
intra-converted to their parent drug, 6-aminocaproic acid, at pH 6.5 (intestine) and pH 7.4 
(blood circulation system) in adequate rates. In vivo pharmacokinetic studies will be done 
in order to determine the bioavailability and the duration of action of the tested prodrugs 
and those predicted to be intraconverted in the intestine and blood circulation. 
.  
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 الملخص
 
بحتة   ةر   هة    ،إرة  مممو ة  كيميائية  هو مادة كيميائية  تة ف هت ةا  اةع ار تةا   اةاهميا   )gurdorP(
ارممموة  ارم بط  مرق ا ةل  ارخصائص ارفتزيائي  رلدواء رزيادة ارفائدة أو  تلتل امت  ا. تمب أن ت ف 
إرة  كةكلا ارطكةع مةن قلأةل ا ية وع أو ار مليةاا ار يميائية  داخةل ارماةف، مةن  )gurdorP(ة حويةل ارة
ار ةةةم  ا طزيمةةةااةلةة  ةمليةة  ار م تةةل اربةةة ائم أو بااةة خداف  بالاة مةةاد ةة ف ةمليةة  ار حويةةةل  أنارممكةةن 
مكةكل   أو قةد  ه ة  ،وزةا هم مميع أطحاء ارماف. هة   انطزيمةاا قةد  تلةل إمةا ار ةواه  ارحتةوء رلةدواء
 ه اريةة  ةلةة  وبار ةةارم  ةةر   ،)gurdorP(ة  ةةدد ا كةةكار ارو ا يةة  ممةةا تةةردء إرةة  ار بةةاتن هةةم  ف تةةل ارةة
 حاةةاب هةم ارحاةةالأي  ار يميةاء أاةةارتب ااة خدما ارماضةةي  ارتلتلة  ار تةةود هةم. ةدارماةةا ارةدواء واةةم 
 بحتة  )gurdorP(  صةميفرلم كباا. باا خداف ه   ا داة من ارممكةن  وارمزيئي  ارفتزيائي  ارخصائص
ارةةدواء ارطكةةع  ةةن ط يةةخ  وابةةع داخةةل ارمةةزءء طفاةةا دون أء  ةةدخل مةةن  إرةة  )gurdorP(ةارةةت حةةور 
ومن  ف  ،كالأ ويك امتطوحم  )gurdorP(رة  ة   ف  صميف  )TFD(انطزيماا. لأطاء ةل  حااباا 
)   أ   إر  حد كلأتة  لأد مة  حموضة  t2/1( أنإر  اردواء ا صلم وومد   حويل ه   ا دوي   ما د اا 
) هةةةم حمةةة t2/1(كاطةةةا ارط ةةةائر ار م يلأيةةة  رةةةل )6- dica ciorpaconima1DorPة(ارواةةةع.  رةةة
اةةةةاة   )9.12(، اةةةةاة  )00( كار ةةةةارم) 5(ود مةةةة  حموضةةةة   )25.(ار تد وكلو يةةةةد، د مةةةة  حموضةةةة  
هم حم  با ة  ف  حويلا   ) 2DorP dica  ciorpaconima-6( ااة ، ةل  ار وارم. )524.(و
 )12(كاطةا  )5(د مة  حموضة   وةلة اةاة   50كاطةا 25.د مة  حموضة  ةل   لأتطماار تد وكلو يد، 
 ciorpaconima-6( ،. مةن طاحية  أخة  )1.7( اةاة  لأتطمةا كةان ماة ت   مامةا هةم د مة  ارحموضة 
هةم  ارماة خدم  حةور رلةدواء ارطكةع ةلة  مميةع د مةاا ارحموضة   أءرةف يكةن هطةاك ) 3DorP dica
 ه   ارد اا . 
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